Functional and genetic deconstruction of the cellular origin in liver cancer

Nature Reviews Cancer

Volumn 15, Issue 11, 2015, Pages 653-667

  Marquardt, Jens U ^a   Andersen, Jesper B ^b   Thorgeirsson, Snorri S ^c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; BILE DUCT CARCINOMA; CANCER GENETICS; CANCER GROWTH; GENE MUTATION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENOMICS; HUMAN; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER TUMOR; MALIGNANT TRANSFORMATION; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; RARE DISEASE; REVIEW; RNA EDITING; STEM CELL; TUMOR MICROENVIRONMENT; ANIMAL; CELL DIFFERENTIATION; GENETICS; PATHOLOGY;

ANIMALS; CELL DIFFERENTIATION; HUMANS; LIVER NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84944906098     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc4017     Document Type: Review

References (145)

1. Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128 (2012).
2. El-Serag, H. B. Hepatocellular carcinoma. N. Engl. J. Med. 365, 1118-1127 (2011).
3. Pawlotsky, J. M., Feld, J. J., Zeuzem, S. & Hoofnagle, J. H. From non-A, non-B hepatitis to hepatitis C virus cure. J. Hepatol. 62, S87-S99 (2015).
4. Marquardt, J. U., Galle, P. R. & Teufel, A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J. Hepatol. 56, 267-275 (2012).
5. Razumilava, N. & Gores, G. J. Classification, diagnosis, and management of cholangiocarcinoma. Clin. Gastroenterol. Hepatol. 11, 13-21 (2013).
6. Bridgewater, J. et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J. Hepatol. 60, 1268-1289 (2014).
7. The International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49, 658-664 (2009); erratum 49,1058 (2009)
8. Farazi, P. A. & DePinho, R. A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6, 674-687 (2006).
9. Marquardt, J. U. et al. Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. J. Hepatol. 60, 346-353 (2014).
10. Guichard, C. et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 44, 694-698 (2012).
11. Kan, Z. et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 23, 1422-1433 (2013).
12. Nault, J. C. et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat. Commun. 4, 2218 (2013).
13. Raggi, C., Invernizzi, P. & Andersen, J. B. Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks and biological concepts. J. Hepatol. 62, 198-207 (2015).
14. Li, M. et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat. Genet. 43, 828-829 (2011).
15. Totoki, Y. et al. High-resolution characterization of a hepatocellular carcinoma genome. Nat. Genet. 43, 464-469 (2011).
16. Fujimoto, A. et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 44, 760-764 (2012).
17. Andersen, J. B. et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 142, 1021-1031.e15 (2012).
18. Oishi, N. et al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology 56, 1792-1803 (2012).
19. Sia, D. et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 144, 829-840 (2013).
20. Seok, J. Y. et al. A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition. Hepatology 55, 1776-1786 (2012).
21. Woo, H. G. et al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res. 70, 3034-3041 (2010).
22. Cazals-Hatem, D. et al. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J. Hepatol. 41, 292-298 (2004).
23. Fujii, H. et al. Genetic classification of combined hepatocellular-cholangiocarcinoma. Hum. Pathol. 31, 1011-1017 (2000).
24. Schulze, K. et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet. 47, 505-511 (2015).
25. Jiang, J. H. et al. Clinical significance of the ubiquitin ligase UBE3C in hepatocellular carcinoma revealed by exome sequencing. Hepatology 59, 2216-2227 (2014).
26. Kaposi-Novak, P. et al. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res. 69, 2775-2782 (2009).
27. Holczbauer, A. et al. Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types. Gastroenterology 145, 221-231 (2013).
28. Nault, J. C. et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology 60, 1983-1992 (2014).
29. Tovar, V. et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J. Hepatol. 52, 550-559 (2010).
30. Woo, H. G. et al. Profiling of exome mutations associated with progression of HBV-related hepatocellular carcinoma. PLoS ONE 9, e115152 (2014).
31. Sung, W. K. et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat. Genet. 44, 765-769 (2012).
32. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
33. Totoki, Y. et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat. Genet. 46, 1267-1273 (2014).
34. Chen, Y., Wang, L., Xu, H., Liu, X. & Zhao, Y. Exome capture sequencing reveals new insights into hepatitis B virus-induced hepatocellular carcinoma at the early stage of tumorigenesis. Oncol. Rep. 30, 1906-1912 (2013).
35. Cleary, S. P. et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology 58, 1693-1702 (2013).
36. Huang, J. et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat. Genet. 44, 1117-1121 (2012).
37. Liu, Y. X. et al. Whole-exome sequencing identifies mutated PCK2 and HUWE1 associated with carcinoma cell proliferation in a hepatocellular carcinoma patient. Oncol. Lett. 4, 847-851 (2012).
38. Chen, Y. L. et al. TERT promoter mutation in resectable hepatocellular carcinomas: a strong association with hepatitis C infection and absence of hepatitis B infection. Int. J. Surg. 12, 659-665 (2014).
39. Ding, D. et al. Recurrent targeted genes of hepatitis B virus in the liver cancer genomes identified by a next-generation sequencing-based approach. PLoS Genet. 8, e1003065 (2012).
40. Jhunjhunwala, S. et al. Diverse modes of genomic alteration in hepatocellular carcinoma. Genome Biol. 15, 436 (2014).
41. Shiraishi, Y. et al. Integrated analysis of whole genome and transcriptome sequencing reveals diverse transcriptomic aberrations driven by somatic genomic changes in liver cancers. PLoS ONE 9, e114263 (2014).
42. Zhong, R. et al. Genetic variant in SWI/SNF complexes influences hepatocellular carcinoma risk: a new clue for the contribution of chromatin remodeling in carcinogenesis. Sci. Rep. 4, 4147 (2014).
43. Chan, T. H. et al. A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut 63, 832-843 (2014).
44. Chen, L. et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. Nat. Med. 19, 209-216 (2013).
45. Kang, L. et al. Genome-wide identification of RNA editing in hepatocellular carcinoma. Genomics 105, 76-82 (2015).
46. Andersen, J. B. Molecular pathogenesis of intrahepatic cholangiocarcinoma. J. Hepatobiliary Pancreat. Sci. 22, 101-113 (2015).
47. Wang, P. et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 32, 3091-3100 (2013).
48. Chan-On, W. et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat. Genet. 45, 1474-1478 (2013).
49. Gao, Q. et al. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients. Gastroenterology 146, 1397-1407 (2014).
50. Jiao, Y. et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat. Genet. 45, 1470-1473 (2013).
51. Ong, C. K. et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat. Genet. 44, 690-693 (2012).
52. Sia, D. et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat. Commun. 6, 6087 (2015).
53. Zou, S. et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat. Commun. 5, 5696 (2014).
54. Marquardt, J. U. & Andersen, J. B. Liver cancer oncogenomics: opportunities and dilemmas for clinical applications. Hepat. Oncol. 2, 79-93 (2015).
55. Muisuk, K. et al. Novel mutations in cholangiocarcinoma with low frequencies revealed by whole mitochondrial genome sequencing. Asian Pac. J. Cancer Prev. 16, 1737-1742 (2015).
56. Wu, Y. M. et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 3, 636-647 (2013).
57. Ross, J. S. et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 19, 235-242 (2014).
58. Arai, Y. et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 59, 1427-1434 (2014).
59. Borad, M. J. et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 10, e1004135 (2014).
60. Graham, R. P. et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum. Pathol. 45, 1630-1638 (2014).
61. Klein, W. M. et al. Primary liver carcinoma arising in people younger than 30 years. Am. J. Clin. Pathol. 124, 512-518 (2005).
62. Pilati, C. et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell 25, 428-441 (2014).
63. Nault, J. C., Bioulac-Sage, P. & Zucman-Rossi, J. Hepatocellular benign tumors - from molecular classification to personalized clinical care. Gastroenterology 144, 888-902 (2013).
64. Marquardt, J. U. & Thorgeirsson, S. S. Next-generation genomic profiling of hepatocellular adenomas: a new era of individualized patient care. Cancer Cell 25, 409-411 (2014).
65. Eichenmuller, M. et al. The genomic landscape of hepatoblastoma and their progenies with HCC-like features. J. Hepatol. 61, 1312-1320 (2014).
66. Jia, D. et al. Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex. Hepatology 60, 1686-1696 (2014).
67. Eggert, T. et al. Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: a detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database. United European Gastroenterol. J. 1, 351-357 (2013).
68. Honeyman, J. N. et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 343, 1010-1014 (2014).
69. Cornella, H. et al. Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology 148, 806-818 (2014).
70. Darcy, D. G. et al. The genomic landscape of fibrolamellar hepatocellular carcinoma: whole genome sequencing of ten patients. Oncotarget 6, 755-770 (2014).
71. Yamashita, T. & Wang, X. W. Cancer stem cells in the development of liver cancer. J. Clin. Invest. 123, 1911-1918 (2013).
72. Llovet, J. M. & Bruix, J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48, 1312-1327 (2008).
73. Marquardt, J. U. & Thorgeirsson, S. S. Stem cells in hepatocarcinogenesis: evidence from genomic data. Semin. Liver Dis. 30, 26-34 (2010).
74. Duncan, A. W., Dorrell, C. & Grompe, M. Stem cells and liver regeneration. Gastroenterology 137, 466-481 (2009).
75. Overturf, K., al-Dhalimy, M., Ou, C. N., Finegold, M. & Grompe, M. Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse hepatocytes. Am. J. Pathol. 151, 1273-1280 (1997).
76. Chen, X. & Calvisi, D. F. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am. J. Pathol. 184, 912-923 (2014).
77. Fausto, N. & Campbell, J. S. Mouse models of hepatocellular carcinoma. Semin. Liver Dis. 30, 87-98 (2010).
78. Zender, L. et al. Cancer gene discovery in hepatocellular carcinoma. J. Hepatol. 52, 921-929 (2010).
79. Yimlamai, D. et al. Hippo pathway activity influences liver cell fate. Cell 157, 1324-1338 (2014).
80. Tschaharganeh, D. F. et al. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology 144, 1530-1542.e12 (2013).
81. Fitamant, J. et al. YAP inhibition restores hepatocyte differentiation in advanced HCC, leading to tumor regression. Cell Rep. 10, 1692-1707 (2015).
82. Zhang, N. et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev. Cell 19, 27-38 (2010).
83. Dorrell, C. et al. Prospective isolation of a bipotential clonogenic liver progenitor cell in adult mice. Genes Dev. 25, 1193-1203 (2011).
84. Lemaigre, F. P. Hepatocytes as a source of cholangiocytes in injured liver. Hepatology 59, 726-728 (2014).
85. Malato, Y. et al. Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J. Clin. Invest. 121, 4850-4860 (2011).
86. Sekiya, S. & Suzuki, A. Hepatocytes, rather than cholangiocytes, can be the major source of primitive ductules in the chronically injured mouse liver. Am. J. Pathol. 184, 1468-1478 (2014).
87. Yanger, K. et al. Robust cellular reprogramming occurs spontaneously during liver regeneration. Genes Dev. 27, 719-724 (2013).
88. Sekiya, S. & Suzuki, A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J. Clin. Invest. 122, 3914-3918 (2012).
89. Fan, B. et al. Cholangiocarcinomas can originate from hepatocytes in mice. J. Clin. Invest. 122, 2911-2915 (2012).
90. Zender, S. et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell 23, 784-795 (2013).
91. Tarlow, B. D. et al. Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. Cell Stem Cell 15, 605-618 (2014).
92. Guest, R. V. et al. Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma. Cancer Res. 74, 1005-1010 (2014).
93. Farber, E. Carcinoma of the liver in rats fed ethionine. AMA Arch. Pathol. 62, 445-453 (1956).
94. Opie, E. L. The pathogenesis of tumors of the liver produced by butter yellow. J. Exp. Med. 80, 231-246 (1944).
95. Evarts, R. P., Nagy, P., Marsden, E. & Thorgeirsson, S. S. A precursor-product relationship exists between oval cells and hepatocytes in rat liver. Carcinogenesis 8, 1737-1740 (1987).
96. Kitade, M. et al. Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling. Genes Dev. 27, 1706-1717 (2013).
97. Benhamouche, S. et al. Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev. 24, 1718-1730 (2010).
98. Tschaharganeh, D. F. et al. p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell 158, 579-592 (2014).
99. Saha, S. K. et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature 513, 110-114 (2014).
100. Hsia, C. C., Evarts, R. P., Nakatsukasa, H., Marsden, E. R. & Thorgeirsson, S. S. Occurrence of oval-type cells in hepatitis B virus-associated human hepatocarcinogenesis. Hepatology 16, 1327-1333 (1992).
101. Roskams, T. & Desmet, V. Ductular reaction and its diagnostic significance. Semin. Diagn. Pathol. 15, 259-269 (1998).
102. Akita, H. et al. MYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism. Cancer Res. 74, 5903-5913 (2014).
103. Kakarala, M. & Wicha, M. S. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J. Clin. Oncol. 26, 2813-2820 (2008).
104. Yong, K. J. et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N. Engl. J. Med. 368, 2266-2276 (2013).
105. Hernandez-Gea, V., Toffanin, S., Friedman, S. L. & Llovet, J. M. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 144, 512-527 (2013).
106. He, G. et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 155, 384-396 (2013).
107. Naugler, W. E. et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317, 121-124 (2007).
108. Park, E. J. et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197-208 (2010).
109. Guo, Y., Xu, F., Lu, T., Duan, Z. & Zhang, Z. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat. Rev. 38, 904-910 (2012).
110. Makarova-Rusher, O. V., Medina-Echeverz, J., Duffy, A. G. & Greten, T. F. The yin and yang of evasion and immune activation in HCC. J. Hepatol. 62, 1420-1429 (2015).
111. Wan, S. et al. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology 147, 1393-1404 (2014).
112. Hoshida, Y. et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 359, 1995-2004 (2008).
113. Maeda, S. et al. IkB kinaseb/nuclear factor-kB activation controls the development of liver metastasis by way of interleukin-6 expression. Hepatology 50, 1851-1860 (2009).
114. Elsharkawy, A. M. & Mann, D. A. Nuclear factor-kB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46, 590-597 (2007).
115. Luedde, T. & Schwabe, R. F. NF-kB in the liver - linking injury, fibrosis and hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 8, 108-118 (2011).
116. Marquardt, J. U. et al. Curcumin effectively inhibits oncogenic NF-kB signaling and restrains stemness features in liver cancer. J. Hepatol. 63, 661-669 (2015).
117. Karin, M. Nuclear factor-kB in cancer development and progression. Nature 441, 431-436 (2006).
118. Jakubowski, A. et al. TWEAK induces liver progenitor cell proliferation. J. Clin. Invest. 115, 2330-2340 (2005).
119. Bird, T. G. et al. Bone marrow injection stimulates hepatic ductular reactions in the absence of injury via macrophage-mediated TWEAK signaling. Proc. Natl Acad. Sci. USA 110, 6542-6547 (2013).
120. Boulter, L. et al. Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat. Med. 18, 572-579 (2012).
121. Feng, G. S. Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. Cancer Cell 21, 150-154 (2012).
122. Li, S. C. et al. Cancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor. Cancer Cell. Int. 14, 115 (2014).
123. Lanaya, H. et al. EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat. Cell Biol. 16, 972-981 (2014).
124. Timchenko, N. A. Cell-type specific functions of EGFR are involved in development of hepatocellular carcinoma. Hepatology 62, 314-316 (2015).
125. Hefetz-Sela, S. et al. Acquisition of an immunosuppressive protumorigenic macrophage phenotype depending on c-Jun phosphorylation. Proc. Natl Acad. Sci. USA 111, 17582-17587 (2014).
126. Ji, J. et al. Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma. Hepatology 62, 481-495 (2015).
127. Trautwein, C., Friedman, S. L., Schuppan, D. & Pinzani, M. Hepatic fibrosis: concept to treatment. J. Hepatol. 62, S15-S24 (2015).
128. Coulouarn, C. & Clement, B. Stellate cells and the development of liver cancer: therapeutic potential of targeting the stroma. J. Hepatol. 60, 1306-1309 (2014).
129. Coulouarn, C. et al. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res. 72, 2533-2542 (2012).
130. Kang, N., Gores, G. J. & Shah, V. H. Hepatic stellate cells: partners in crime for liver metastases? Hepatology 54, 707-713 (2011).
131. Gentilini, A. et al. Role of the stromal-derived factor-1 (SDF-1)-CXCR4 axis in the interaction between hepatic stellate cells and cholangiocarcinoma. J. Hepatol. 57, 813-820 (2012).
132. Greten, T. F., Wang, X. W. & Korangy, F. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut 64, 842-848 (2015).
133. Bruix, J., Gores, G. J. & Mazzaferro, V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 63, 844-855 (2014).
134. Quetglas, I. M., Moeini, A., Pinyol, R. & Llovet, J. M. Integration of genomic information in the clinical management of HCC. Best Pract. Res. Clin. Gastroenterol. 28, 831-842 (2014).
135. Sprinzl, M. F. & Galle, P. R. Immune control in hepatocellular carcinoma development and progression: role of stromal cells. Semin. Liver Dis. 34, 376-388 (2014).
136. Sprinzl, M. F. et al. Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion. J. Hepatol. 62, 863-870 (2015).
137. Sangro, B. et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J. Hepatol. 59, 81-88 (2013).
138. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014).
139. Heo, J. et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat. Med. 19, 329-336 (2013).
140. Le, D. T. et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J. Clin. Oncol. 33, 1325-1333 (2015).
141. Wang, J., Reiss Binder, K., Khatri, R., Jaffee, E. & Laheru, D. Immune therapy in GI malignancies: a review. J. Clin. Oncol. 33, 1745-1753 (2015).
142. Bruix, J., Han, K. H., Gores, G., Llovet, J. M. & Mazzaferro, V. Liver cancer: approaching a personalized care. J. Hepatol. 62, S144-S156 (2015).
143. Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245-1255 (2012).
144. Rizvi, S. & Gores, G. J. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology 145, 1215-1229 (2013).
145. Qian, M. B., Utzinger, J., Keiser, J. & Zhou, X. N. Clonorchiasis. Lancet http://dx.doi.org/10.1016/S0140-6736(15)60313-0 (2015).